All News

virus,injection,COVID,vaccine

FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines

d Jack Cush, MD

Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.

Read Article
MTP1,gout

NICE Guidelines on Gout Diagnosis and Management

d Jack Cush, MD

NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.

Read Article
sleep.awake_.woman_.jpg

Prevalent Sleep Problems in Rheumatoid Arthritis

d Jack Cush, MD

Data from Data FORWARD (The National Databank for Rheumatic Diseases) reveals that nearly two-thirds of rheumatoid arthritis (RA) patients have self-reported sleep problems.

Read Article
LiveVote.jpg

Disease Activity Scoring in Adult-onset Still's disease

d Jack Cush, MD

Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessments). A new study compares two such activity measuresin a large cohort of Still's patients.

Read Article
ANCA.jpg

STING/IFN Activation Promotes ANCA-Associated Vasculitis Progression

d Jack Cush, MD

Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.

Read Article
heart.EKG_.CVD_.jpg

Autoimmune Disease Augments Cardiovascular Risk

d Jack Cush, MD

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.

Read Article
Life expectancy for Americans is the lowest it's been since 1996. Read about the decline from @sheridan_kate https://t.co/QwkOmOt2Tp https://t.co/wavGjOv6q5

Links:

STAT statnews ( View Tweet)
Statin Myalgias? Lancet metanalysis of 19 PCTs, >80K pts, @ 1yr, Statin caused a 7% increase in muscle pain or weakness (1·07; 1·04–1·10); thus 1 in 15 had myalgia due to statin (1/10 w/ high dose). After year 1, no signif excess in statin related myalgia https://t.co/6cRJQMymzM https://t.co/RTH56J4FD1

Links:

Dr. John Cush RheumNow ( View Tweet)
After historic drop in 2020 (COVID), life expectancy in USA dropped again, this time a full year to 76.1 years. The lowest since 1996 and the biggest 2-year decline in a century (dropping >2.5 yrs). To date, there have been 1,044,937 COVID deaths in USA https://t.co/aSgtw6MvGs https://t.co/0UKeyGujKe

Links:

Dr. John Cush RheumNow ( View Tweet)
Tapering biologics in Still's/Systemic JIA? 4 studies suggests after sustained inactive disease achieved, options include QOD (anakinra) dosing or dose reduction or interval prolongation (CAN & TCZ). KEY: early biologic starts https://t.co/33tjr65Gi0 https://t.co/fi6fc4NPgG

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of Adult-onset Still's in Western Australia. Incidence = 0.22/100 000, prevalence = 2.4/100 000. AOSD had higher risk of previous liver disease (OR 2.67), serious infx (OR 4.36), joint replacement (OR 45.5), mortality not increased @ 1 & 5 yrs https://t.co/Wu0SQIMjWT https://t.co/Zvsdb2OR0y

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoimmune Disease Augments Cardiovascular Risk A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease. https://t.co/TtiH9ZBkR8 https://t.co/jVZBk8l4XD

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of cGAS/STING - enzyme cyclic GMP-AMP synthase. self genomic & mitochondrial DNA stimulates cGAS-->dimerizes & binds to the endoplasmic reticulum protein stimulator of IFN genes (STING), unleashing an inflammatory response https://t.co/g04v1S4PYJ https://t.co/SHeneZq4sd

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/EQJV4qTFPj https://t.co/Rdkn4ljh0X

Links:

Dr. John Cush RheumNow ( View Tweet)
USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/XEaXqcCEg1 https://t.co/vEqEFV1kYv

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy - Steroid use "for irAEs may not have a large deleterious effect on overall survival" - DMARDs for irAE "a major drawback in the delay in the onset of response" https://t.co/YciXN4fdZQ https://t.co/oNgszsYNB8

Links:

Dr. John Cush RheumNow ( View Tweet)
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/4Hew7zVu7J https://t.co/za9hQ8Plnl

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 124 adults hospitalized w/ acute MSK trauma saw good outcomes in 23% @6 mos & 61% @12 mos. Worse outcomes assoc w/ posttraumatic stress Sxs (OR 2.09), pain intensity (2.87), # fractures (2.79)& pain extent (4.67) https://t.co/ubuyWCBFgU https://t.co/ZfNGUQ1i0e

Links:

Dr. John Cush RheumNow ( View Tweet)
Influenza Vaccination Recommendations The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season. https://t.co/6V21XZUsqX https://t.co/ln9bqta6UT

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/lSvnAkRvxB https://t.co/i7ZORYyKHP

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×